SEC Contract Filing

Filing Date: 2024-03-13

Document Content:
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>4
<FILENAME>sldb-ex10_15.htm
<DESCRIPTION>EX-10.15
<TEXT>
<html>
 <head>
 <title>EX-10.15</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
 <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.15</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
 <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
 <tr style="visibility:collapse;">
 <td style="width:26.92%;"></td>
 <td style="width:73.08%;"></td>
 </tr>
 <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
 <td style="text-indent:42pt;vertical-align:top;"><p style="margin-left:42pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Solid Biosciences Inc.</font></p></td>
 <td style="vertical-align:top;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
 </tr>
 <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
 <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Executive Chairman Agreement</font></p></td>
 <td style="vertical-align:top;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
 </tr>
 </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
 <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:30pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXECUTIVE CHAIR AGREEMENT</font></p>
 <p style="text-indent:6.711%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Executive Chair Agreement (together with Exhibit A, the &#x201c;Agreement&#x201d;), effective January 1, 2022 (the &#x201c;Effective Date&#x201d;), is by and between Ian F. Smith, an individual having an address at 45 Commonwealth Avenue, Unit 3, Boston, MA 02116 (the &#x201c;Executive Chair&#x201d;), and Solid Biosciences Inc., a Delaware corporation (together with its affiliates, the &#x201c;Company&#x201d;), having an address at 141 Portland Street, Fifth Floor, Cambridge, MA 02139.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
 <p style="text-indent:6.711%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, Executive Chair is currently serving as a member and chairman of the Board of Directors of the Company (the &#x201c;Board&#x201d;);</font></p>
 <p style="text-indent:6.711%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, Executive Chair has also been providing advisory services to Company pursuant to a consulting agreement between the Parties entered into on January 4, 2021 (the &#x201c;Prior Agreement&#x201d;) and both parties acknowledge and agree that, as of the Effective Date of this Agreement, the agreed upon services under the Prior Agreement have been completed;</font></p>
 <p style="text-indent:6.711%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, from and after the close of business on the Effective Date, Executive Chair shall no longer serve under the Prior Agreement, but shall be retained as the Executive Chairman pursuant to the terms and conditions set forth herein; and</font></p>
 <p style="text-indent:6.711%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:0.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NOW THEREFORE, in consideration of the promises and mutual covenants herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Executive Chair and the Company agree as follows:</font></p>
 <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="wid